Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatment

25 Feb 2025

Abstract excerpt

BACKGROUND: The emergence of targeted therapies and immunotherapy has broadened treatment options for patients with pancreatic ductal adenocarcinoma (PDAC). Despite this, traditional drug selection, predominantly relies on tumor markers and clinical staging, has underutilized these drugs due to ignoring patient genomic diversity. Patient-derived organoids (PDOs) and corresponding patient-derived organoid...

Topics

Join the communities discussing this publication.

Cancer Cells and Metastasis
Cancer Immunotherapy and Biomarkers
Ferroptosis and cancer prognosis

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40001264
DOI: 10.1186/s13046-025-03332-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentPMID 40001264Read ↗

Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses.Semantic proximity Read ↗

Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoidsSemantic proximity Read ↗

Pancreatic adenocarcinoma human organoids share structural and genetic features with primary tumorsSemantic proximity Read ↗

Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma TumorsSemantic proximity Read ↗

Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug RepurposingSemantic proximity Read ↗

Patient-derived urachal cancer organoids for personalized drug screeningSemantic proximity Read ↗

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerSemantic proximity Read ↗

The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy.Semantic proximity Read ↗

The Diverse Applications of Pancreatic Ductal Adenocarcinoma OrganoidsSemantic proximity Read ↗

Correlation Between Drug Sensitivity Profiles of Ex Vivo Expanded Circulating Tumor Cells and Clinical Treatment Response in Pancreatic Ductal Adenocarcinoma PatientsSemantic proximity Read ↗

Patient-derived Tumor Xenograft and Organoid Models Established from Resected Pancreatic, Duodenal and Biliary CancersSemantic proximity Read ↗

Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.